Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282834 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HTR2CPSMB8KDRROCK2 | |
| SCHEMBL3282828 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2HTR2CPSMB8KDRROCK2 | |
| SCHEMBL5551875 | 0.80 | MEN1 (0.50) | MEN1TSHRKMT2A | |
| SCHEMBL5547801 | 0.80 | MEN1 (0.53) | MEN1TSHRKMT2A | |
| SCHEMBL20094558 | 0.77 | KDR (0.51) | SMN1; SMN2HTR2CPSMB8KDRTERT | |
| SCHEMBL21580333 | 0.77 | SCN3A (0.52) | PSMB8KDRMEN1KMT2AULK1 | |
| SCHEMBL20094557 | 0.77 | KDR (0.51) | SMN1; SMN2HTR2CPSMB8KDRTERT | |
| SCHEMBL20094229 | 0.77 | KDR (0.51) | SMN1; SMN2HTR2CPSMB8KDRTERT | |
| SCHEMBL4052121 | 0.77 | CTSC (0.43) | HTR2CPSMB8ROCK2TERTULK1 | |
| SCHEMBL5552001 | 0.76 | MEN1 (0.46) | MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709501-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149513-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | SMN1; SMN2 2694/4885HTR2C 130/4885PSMB8 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.